Cytomedix Inc., of Gaithersburg, Md., said data from a randomized Phase I trial of ALD-201 in ischemic heart failure were published in the online edition of the American Heart Journal. The study enrolled 20 heart failure patients with no treatment options, evaluating safety as the primary endpoint.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter